About this trial
The purpose of the De-Escalate trial is to determine whether intermittent hormonal combintation treamtment provides a favorable risk/benefit balance compared with continuous maximum androgen blockade (cMAB) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who achieve a deep PSA response (≤ 0.2 ng/mL) after 6–12 months of treatment with ADT plus an approved androgen receptor pathway inhibitor (ARpI).
Patient Profile
For patients being treated for prostate cancer that has spread (metastatic) and who have had a good response to a standard of care hormonal combination treatment
Where’s this trial being run?
Beacon Hospital, Beaumont Hospital, Cork University Hospital, St James’s Hospital, Tallaght University Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Galway, Mater Misericordiae University Hospital, and Mater Private Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | De-Escalate |
|---|---|
| Number: | 24-32 |
| Full Title: | Intermittent Androgen Deprivation Therapy in the era of Androgen Receptor pathway inhibitors; a phase III pragmatic randomized trial |
| Principal Investigator: | Prof Ray McDermott (SVUH) |
|---|---|
| Type: | Collaborative |
| Sponsor: | EORTC |
| Recruitment Started: |
Global: May 25 Ireland: Dec 25 |
| Global Recruitment Target: | 1600 |
|---|---|
| Ireland Recruitment Target: | 144 |